Nitroglicerina Teva

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitroglicerina Teva

What is Nitroglicerina Teva?

Nitroglicerina Teva is a medicinal product containing nitroglycerin, a substance that belongs to the class of medications known as organic nitrates. It is primarily utilized for its effects on the cardiovascular system, specifically its ability to act as a potent vasodilator.

Mechanism of Action

The active ingredient, nitroglycerin, works by relaxing the smooth muscle tissues within the walls of blood vessels. This relaxation leads to the dilation of both arteries and veins. By widening these vessels, the medication facilitates several physiological changes:

  • Reduction in Cardiac Workload: Vasodilation reduces the resistance the heart must pump against and decreases the volume of blood returning to the heart.
  • Improved Oxygen Delivery: The dilation of coronary arteries enhances the flow of oxygen-rich blood to the heart muscle (myocardium).
  • Blood Pressure Modulation: The systemic expansion of blood vessels results in a lowering of systemic vascular resistance.

Therapeutic Intent

Nitroglicerina Teva is designed to address conditions where the oxygen supply to the heart is insufficient to meet its demands. This imbalance often manifests as chest pain or discomfort. The medication is formulated to provide rapid onset of action to manage acute episodes or to provide sustained release for the long-term management of chronic vascular conditions.

Pharmaceutical Form

As part of the Teva pharmaceutical portfolio, this medication is produced in various formulations to suit different clinical requirements. These may include sublingual forms for immediate effect during acute symptoms or transdermal patches designed for the continuous, slow release of the active substance through the skin into the bloodstream.

Regulatory References

  1. Nitroglycerin (Glyceryl Trinitrate) Drug Information

What side effects are possible with Nitroglicerina Teva?

Possible Side Effects and Safety Information

The safety profile for Nitroglicerina Teva (glyceryl trinitrate) is documented in official regulatory sources, with adverse reactions classified by frequency and System-Organ Class (SOC). The most commonly reported effects are directly related to the drug's potent vasodilating action, primarily impacting the vascular and nervous systems.


Frequency-Classified Adverse Reactions

The following effects are classified according to frequency in regulatory documents:

  • Very Common: Headache (often described as dose-related and typically subsides with continued therapy).
  • Common: Dizziness, Tachycardia (increased heart rate), and Orthostatic Hypotension (a drop in blood pressure upon standing).
  • Uncommon: Nausea, Vomiting, Syncope (fainting), Facial Flushing, and Circulatory Collapse.
  • Very Rare: Methaemoglobinaemia (a blood disorder), Exfoliative Dermatitis, and Drug Rash.

Serious Adverse Reactions and Restrictions

Certain severe, though less frequent, events are noted in official labeling. These include Severe Hypotension which may lead to Circulatory Collapse or Syncope. Methaemoglobinaemia is documented as a very rare but clinically serious blood disorder.

Use of this medicine is strictly restricted in certain circumstances. It is contraindicated for use with Phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil) due to the risk of life-threatening hypotension. It is also restricted in patients with severe anemia and conditions involving increased intracranial pressure.


Time-Related and Population Safety Notes

Regulatory documents note that effects such as headache and orthostatic hypotension are often more pronounced at the start of therapy and may diminish over time. Safety and effectiveness have not been established in pediatric patients, and caution is advised for older adults who may have increased sensitivity to blood pressure changes, according to regulatory guidelines.

Overdose and Emergency Response

The official regulatory profile for a Nitroglicerina Teva (Glyceryl trinitrate) overdose is defined by symptoms resulting from an exaggerated pharmacological effect. Documented manifestations include severe hypotension, a persistent throbbing headache, vertigo, weakness, and syncope (fainting). Severe outcomes leading to potential life-threat include circulatory collapse, coma, convulsions, and Methemoglobinemia, which can occur with massive doses.

Immediate medical attention must be sought for any suspected overdose or upon the onset of these severe symptoms. The regulatory labeling states that no specific antagonist to the vasodilatory effects is known. Management focuses on symptomatic and supportive treatment, including the intravenous increase in central fluid volume and the administration of activated charcoal if ingestion was recent. Continuous monitoring of vital signs, including the electrocardiogram (ECG) and central venous pressure, is required. Population-specific notes indicate that elderly patients are more susceptible to severe hypotension, and treatment may be complicated in those with pre-existing heart failure.

Therapeutic Uses of Nitroglicerina Teva

Quick Facts

  • Targeted Relief: Helps manage episodes of chest discomfort (angina pectoris).
  • Prevention: May be used to help prevent anticipated angina attacks.
  • Condition Focus: Supports the management of symptoms associated with coronary artery disease.

Nitroglicerina Teva is a pharmaceutical agent prescribed to address certain cardiovascular concerns. Its primary therapeutic role involves the relief of an acute episode of angina pectoris, commonly known as chest pain, which is typically associated with reduced blood flow to the heart muscle due to coronary artery disease. The medication may also be used for the prophylaxis (prevention) of anticipated anginal symptoms, particularly before activities that may commonly trigger an attack.

It is a recognized component in the management strategies for patients with this condition, helping to manage discomfort and improve symptom profile.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Nitroglycerin Teva

Eligibility for nitroglycerin is strictly defined by regulatory bodies based on the risk of severe complications, primarily related to drug interactions and pre-existing medical conditions.

Nitroglycerin must not be used (is contraindicated) in patients who are currently taking a selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5 inhibitors), such as sildenafil or tadalafil, or a soluble guanylate cyclase (sGC) stimulator (e.g., riociguat), due to the risk of life-threatening hypotension.

Contraindicated Conditions

Use is also prohibited in individuals with known hypersensitivity to nitrates, severe anemia, increased intracranial pressure (such as from cerebral hemorrhage or head trauma), acute circulatory failure or shock, and certain types of early myocardial infarction.

Use with Caution and Restrictions

  • Pediatric Patients: The safety and effectiveness of this medicine have not been established in pediatric patients.
  • Older Adults: Dosage should be selected cautiously and typically started at the lower end of the range due to the potential for decreased organ function.
  • Pregnancy and Lactation: Data are insufficient to determine drug-associated risk during pregnancy, and it is not known if the drug is present in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Nitroglicerina Teva (Glyceryl Trinitrate) details specific interaction patterns, primarily categorized by pharmacokinetic and pharmacodynamic effects.

Contraindicated Combinations

Co-administration with Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil, vardenafil) is strictly contraindicated due to the risk of severe, life-threatening hypotension. Similarly, combination with Soluble Guanylate Cyclase (sGC) Stimulators (e.g., riociguat) is prohibited for the same reason.

Mandatory Timing-Based Separation: Administration of Nitroglicerina Teva must be separated by at least 24 hours or 48 hours following the use of certain PDE-5 inhibitors, as specified in regulatory documents.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance Official Interaction Outcome
Antihypertensive Drugs (e.g., ACE-inhibitors, Beta-blockers) Possible additive hypotensive effects documented in labeling.
Ergot Alkaloids (oral administration) Oral nitroglycerin decreases the first-pass metabolism of dihydroergotamine, thereby increasing its oral bioavailability.
Intravenous Heparin Nitroglycerin administration reduces the anticoagulant effect of heparin.
Alcohol Concomitant use may cause hypotension.

High-dose Aspirin may also enhance the vasodilatory effects of nitroglicerina. These statements reflect the official interaction profile as defined by government regulatory agencies.

Mechanism of Action

️ Molecular Activation and Nitric Oxide Release

The drug's active ingredient, Glyceryl Trinitrate (GTN), functions as an inactive prodrug that requires enzymatic conversion. This transformation occurs primarily within vascular cells, mediated by Mitochondrial Aldehyde Dehydrogenase 2 (ALDH2). This enzymatic reductive cleavage of GTN results in the release of the endogenous signaling molecule, Nitric Oxide (NO). NO acts as a messenger, initiating the subsequent cascade of smooth muscle relaxation.

️ The cGMP-PKG Cascade and Vascular Relaxation

The released NO immediately targets the enzyme Soluble Guanylate Cyclase (sGC) inside the vessel cells, activating a specific cascade that increases levels of the second messenger cGMP. This increase activates Protein Kinase G (PKG), which ultimately inhibits the mechanism necessary for muscle contraction, causing the vascular smooth muscle cells to relax and widen the blood vessels (vasodilation).

️ Systemic Effect: Modulation of Cardiac Preload

This widespread vasodilation is most pronounced in the veins, causing blood to pool and subsequently reducing venous return to the heart. This physiological change decreases the volume load on the heart, known as reduced cardiac preload, which minimizes the effort and energy required for ventricular contraction. This mechanism modulates the body's systemic hemodynamic dynamics.

Dosage and Administration Information

How to use Nitroglicerina Teva

The administration of Nitroglicerina Teva (glyceryl trinitrate) involves distinct patterns based on the required speed and duration of action. Usage occurs across multiple routes, including sublingual and lingual for rapid effects, and oral, topical, or transdermal routes for sustained management.


Administration Protocol and Dosing Schedule

Entity Usage Summary
Acute Relief Dosing Strictly limited to a maximum of three doses (0.3 mg to 0.6 mg tablet or 400 mcg spray) when administered within a 15-minute period, used on an as-needed basis.
Chronic Cyclic Regimen Maintenance therapy, such as with extended-release capsules or transdermal patches, requires a mandatory 10 to 12 hour drug-free interval daily to ensure preservation of therapeutic response.
Intravenous (IV) Use Reserved for controlled settings, requiring initial dilution and continuous delivery via an infusion pump using non-absorptive tubing.
Population Rules Dosing for older adults must be initiated cautiously, often starting at the low end of the labeled range.

Specific Procedural Constraints

The required method of administration dictates specific procedural constraints. For instance, extended-release oral capsules must be swallowed whole and are not to be crushed or chewed, ensuring the intended rate of release. Transdermal patches must be applied to the skin and are explicitly instructed not to be cut or trimmed. The overall use protocol is defined by this distinction: acute, intermittent use is constrained by immediate time limits, while chronic maintenance is structured by a necessary daily cycle.

Recent Clinical Evidence

Nitroglicerina Teva: Recent Clinical Evidence

Research focusing on nitroglycerin's role, including its application in formulations such as Nitroglicerina Teva, centers primarily on its use in angina pectoris (chest pain) and certain acute cardiovascular conditions. This compound has a long history of clinical use, and recent studies have focused on optimizing delivery systems and evaluating its role in specific patient subsets.

Mechanism of Action Studied

Studies examined the drug's vasodilatory role, noting that its influence on vascular smooth muscle leads to relaxation and widening of both peripheral veins and coronary arteries. This process results in a reduction of cardiac workload and an increase in blood flow to the heart muscle, an effect examined in numerous clinical settings.


Key Findings from Clinical Research

Randomized Controlled Trials (RCTs) continue to be the main study design, examining outcomes when nitroglycerin is administered to relieve acute angina symptoms or manage hypertensive crises. Research has also explored its use as a preventative measure in patients with stable angina.

Efficacy and Outcome Assessment

Outcome Measure Research Focus
Symptom Resolution Time to relief of acute anginal pain following administration
Hemodynamics Influence on blood pressure, heart rate, and cardiac output

Studies evaluated whether the drug influences the frequency and severity of anginal episodes, particularly when used sublingually. Data analysis reported findings regarding the magnitude of observed pain reduction compared with placebo or standard supportive care. Tolerance to the treatment, characterized by a diminished response over time, is a well-documented phenomenon that research continues to address.


Safety and Tolerability Data

The safety profile was assessed across various patient populations. The most common adverse events reported are related to its vasodilatory action, primarily headache and hypotension (low blood pressure). Studies emphasized the necessity of careful patient monitoring, particularly in the immediate post-administration period.

Frequently Asked Questions (FAQ)

Common questions about Nitroglicerina Teva (FAQ)


Q: How quickly is the medicine supposed to start working?

A: Regulatory documents indicate that sublingual forms of this medication are designed for rapid action. The vasodilatory effect (widening of blood vessels) typically begins within 1 to 3 minutes after administration. The maximum effect is generally observed within 5 minutes, consistent with its purpose for rapid intervention.


Q: What is the typical duration of effect for a dose of Nitroglicerina Teva?

A: Sublingual preparations are used for acute, short-term relief, and their effects are usually brief. Official prescribing information indicates that the benefit from a single dose typically lasts for approximately 30 to 60 minutes. This short duration is why chronic management often involves different, longer-acting formulations.


Q: Is it possible to become tolerant to the effects of Nitroglicerina Teva over time?

A: Yes, regulatory documentation acknowledges that tolerance, which is a diminished response to the medicine, can occur with continuous use of nitrates. A daily nitrate-free interval is structured into chronic treatment to help manage this effect.


Q: Is there a maximum amount of Nitroglicerina Teva that can be used in a 24-hour period?

A: For the acute relief of chest pain, the use of rapid-acting forms is restricted. Official guidelines specify a limit of three doses within a 15-minute period. Regulatory documents also define maximum daily doses and required 'off-periods' for sustained-release forms used for preventative purposes.


Q: Is it necessary to avoid alcohol completely when taking Nitroglicerina Teva?

A: Official product information states that consuming alcohol while using this medicine may cause hypotension, or dangerously low blood pressure. Due to this potential additive blood pressure-lowering effect, official guidance suggests limiting or avoiding alcohol consumption due to this risk.


Q: What does the patient information say about use during pregnancy?

A: The official labeling indicates that limited published data are insufficient to determine a drug-associated risk to the fetus if used during pregnancy. Official documents indicate that use is generally weighed against the potential risks.


Q: What does the patient information say about use while breastfeeding?

A: Official labeling states that it is not known if the active drug is present in human milk or if its presence could affect the breastfed infant. These factors are typically evaluated by a health professional.


Q: Can older adults typically use Nitroglicerina Teva safely?

A: Yes, older adults can use the medicine, but regulatory documents advise that dosage should be selected cautiously. Older adults may have increased sensitivity to blood pressure changes, so the starting dose is often recommended to be at the lower end of the official dosing range.


Q: Is it common to feel a burning or tingling sensation after using the sublingual form?

A: Official patient instructions indicate that a burning or tingling sensation under the tongue may be felt as the sublingual tablet dissolves. However, official information notes that this specific feeling is not a reliable indicator of the medicine's potency or effect.


Q: What are the official recommendations regarding driving and operating machinery while using this drug?

A: Because the medication can cause side effects such as dizziness, lightheadedness, and low blood pressure, official warnings state that a patient’s ability to drive or operate machinery may be impaired. This risk is considered highest when therapy begins or after a dosage change.


Q: What conditions or diseases are listed where this medicine should be used with caution?

A: Official safety warnings list conditions that require cautious use. These include pre-existing low blood pressure (hypotension), recent heart attack or acute circulatory failure, and certain conditions affecting heart muscle, such as hypertrophic cardiomyopathy.


Q: Does Nitroglicerina Teva interact with aspirin or other common anti-platelet drugs?

A: Official labeling notes that high-dose Aspirin may enhance the vasodilating effects of nitroglycerin, possibly leading to lower blood pressure. Information about all drug combinations is relevant for professional review.


Q: Are there any common foods or supplements that might interact with this medicine?

A: Official government health resources sometimes note that certain dietary supplements or foods that significantly affect blood pressure, such as high-dose L-arginine, may have an additive effect when combined with this drug. This information is usually discussed within the context of overall care.


Q: What are the rules about using Nitroglicerina Teva before strenuous physical activity?

A: Official instructions state that rapid-acting forms of the medicine may be used prophylactically (preventatively). The medication can be administered 5 to 10 minutes before engaging in any activity that is known to typically trigger an anginal attack.


Q: Does the form of the medicine (e.g., tablet, spray) change how fast it works?

A: Both the sublingual tablet and the sublingual spray are formulated for rapid relief. Official regulatory documents indicate that the onset of action for both forms, when administered correctly, is typically rapid, often starting within 1 to 3 minutes.


Q: Can Nitroglicerina Teva interact with common over-the-counter pain relievers?

A: Drug interaction checkers in government health resources generally indicate no major interaction with common non-prescription pain relievers like acetaminophen. However, caution is advised for any combination that might influence blood pressure, and these combinations are usually evaluated as part of overall treatment management.


Q: What happens if I accidentally use the medicine too close together?

A: Exceeding the recommended dosage limit may lead to symptoms related to overdose described in official documents. These effects may include severe low blood pressure, intense flushing, a pounding headache, and, very rarely, a serious blood condition known as methemoglobinaemia.


Q: Can Nitroglicerina Teva interact with herbal remedies like St. John's Wort?

A: While not always specified on the primary label, official drug interaction resources advise that some herbal remedies, such as St. John’s Wort, may interfere with the metabolism of many medicines. Information on combination use is generally evaluated by a health professional.


Q: How often do patients typically need to use Nitroglicerina Teva?

A: The required frequency is determined by the patient's condition as defined in regulatory documents. Use is categorized as either 'as-needed' for the relief of acute chest pain, or 'scheduled and cyclic' for the long-term, preventative management of symptoms.


Q: Is there a specific time of day that is better for using this medicine?

A: For sustained-action forms (like patches or extended-release capsules), official instructions mandate a daily 10 to 12 hour drug-free interval to prevent tolerance. Many patients arrange their dosing schedule to ensure this nitrate-free period occurs during the night.


Q: What are the typical instructions for what to do after the first dose if symptoms do not improve?

A: Official patient instructions recommend that if chest pain is not relieved after the first dose of the sublingual form, a second dose may be administered 5 minutes later. If pain still persists after a total of three doses over 15 minutes, official documents indicate that prompt medical attention is necessary.


Q: Is it true that this drug has been around for a long time?

A: Yes, official medical literature often notes that the active ingredient, nitroglycerin, has a long history of clinical use. Its use in medicine dates back to the late 19th century, establishing it as one of the oldest treatments in cardiovascular therapy.


Q: Can the patches or topical forms of nitroglycerin also be used for immediate chest pain relief?

A: No. The regulatory indication for transdermal patches and topical ointment is for the prophylactic (preventative) management of symptoms. These forms are not intended for or effective for the immediate, acute relief of an attack.


Q: How does Nitroglicerina Teva differ from blood thinners?

A: Official drug classification lists Nitroglicerina Teva as a nitrate vasodilator, meaning its primary function is to widen blood vessels. It is not classified as an anticoagulant (blood thinner), which prevents clotting. However, official labeling does note it can affect the action of some intravenous blood thinners.


Q: Is it safe to use Nitroglicerina Teva if I have kidney problems?

A: While kidney problems are not a primary contraindication, official documents advise caution in patients with conditions that make them sensitive to changes in blood pressure, including some patients with kidney impairment. The body uses the kidneys to excrete the drug's byproducts.


Q: Is it safe to use Nitroglicerina Teva if I have liver problems?

A: Liver problems are not listed as a primary contraindication, but the drug is primarily metabolized (processed) by the liver. Official documents advise caution in patients with conditions that make them sensitive to blood pressure changes, which may include some patients with severe liver impairment.

How should Nitroglicerina Teva be stored and disposed of?

Official Storage and Disposal Requirements

Nitroglycerin Sublingual Tablets must be stored strictly according to regulatory guidelines to maintain potency. The official requirement is to store the product at Controlled Room Temperature, typically between 20^circC and 25^circC (68^circF and 77^circF).

Storage Constraints

Requirement Constraint
Temperature Do not freeze or expose to excessive heat.
Container Must be kept in the original glass container, tightly closed immediately after each use.
Environment Protect from moisture and direct light.
Child Safety Keep this and all medications out of the reach of children.

Disposal Protocol

Unused or expired medication must be handled according to specific rules. Do not dispose of the tablets in household trash or flush them down the toilet. Instead, consult a pharmacist or healthcare provider for instructions on local take-back programs or safe disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitroglicerina Teva found in:

A-Z Index: